P2Y12 antibody inhibits platelet activity and protects against thrombogenesis.

Nicole R. Hensch,Zubair A. Karim,Joshua Pineda,N. Mercado,F. Alshbool,F. Khasawneh

DOI: https://doi.org/10.1016/j.bbrc.2017.09.083

2017-11-18

Abstract:

What problem does this paper attempt to address?

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Vincent Law,Colin Snyder,Zhihua Chen,Pawel Kalinski,Brian J. Czerniecki,Peter A. J. Forsyth

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.2030

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:2030 Background: Approximately 5% of advanced stage breast cancer (BC) will develop leptomeningeal disease, a rare form of metastasis in the meninges, a membrane surrounding the brain and spinal cord. The prognosis for BC-LMD is dismal and currently available treatments are ineffective. For example, intrathecal (IT) therapy such as trastuzumab, and proton cranial spinal radiotherapy have only showed modest success. Dendritic cells are a master regulator of the immune system and play a critical role in bridging the innate and adaptive immune response. Here, we used a novel preclinical model to administer MHC class II peptide-pulsed conventional Type 1 dendritic cells (cDC1s) intrathecally in mice that harbor either HER2+ or triple negative breast cancer (TBNC) LMD. Our murine BC-LMD murine data lead us to open a Phase 1 clinical trial of cDC1s in HER2+ and TNBC LMD (NCT05809752; in progress). Methods: Our lab developed a “murine Ommaya” which mimics the clinically used Ommaya reservoir and allows for repeated intrathecal (IT) injections of novel drugs at 3 – 7µl volume directly into the CSF. We next developed a pipeline for screening immunogenic MHC class II peptides from tumor-associated oncodrivers and using these targets to generate tumor-targeting cDC1s. We tested the resulting vaccines in a preclinical model that IT delivers peptide-pulsed cDC1 cell therapy directly into the BC-LMD microenvironment. Results: We tested the efficacy of treatment in HER2+ LMD and TNBC-LMD models and found effective responses; LMD mice that received IT cDC1 therapy exhibited reduced tumor burden and prolonged survival that was significantly better than systemic therapy. Approximately 70% of mice from HER2+ LMD and 30% from TNBC LMD demonstrated complete responses. This was CD4+ T cell dependent. Notably, cured mice also showed signs of resistance against LMD recurrence upon rechallenge. Subsequent single cell RNA-seq (scRNA-seq) analyses of the CSF showed a shift in the innate immune landscape found in untreated LMD to an adaptive immune landscape. In addition, we noted the elevated secretion of Th1 proinflammatory cytokines such as IFN-γ in the CSF. This was recapitulated in the CSF samples of patients enrolled in an on-going phase 1 trial, where early data showed IT cDC1 triggered a high concentration of several proinflammatory cytokines. Conclusions: Our preclinical data suggest IT cDC1 vaccine is effective against BC-LMD and prevents LMD recurrence. We are currently investigating the mechanism(s) by which IT cDC1-initiates the CD4 Th1 adaptive immune response against LMD. By employing an scRNA-seq approach, we hope to further determine the roles of different immune cells and their subtypes in the CSF to IT cDC1s in mice and in patients. A future approach includes testing IT cDC1 platform in LMD from other cancers (e.g. melanoma etc.).
Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Wp Zhang,L He,Zl Yuan,Zf Xie,Jl Wang,H Hamada,Xt Cao

DOI: https://doi.org/10.1089/10430349950018148

1999-01-01

Human Gene Therapy

Abstract:Pulsing dendritic cells (DCs) with tumor cell-derived mRNA is regarded as an attractive alternative in the development of DC-based tumor vaccines. Our aim is to improve the therapeutic efficacy of DC-based tumor RNA vaccines by augmenting the preferential chemotaxis of DCs to T cells. Mouse bone marrow-derived DCs were genetically modified with lymphotactin (Lptn) by adenovirus vector, which conferred on DCs preferential chemotaxis to CD4(+) and CD8(+) T cells (Cao et al., 1998), Lptn gene-modified DCs (Lptn-DCs) were pulsed with tumor mRNA and used for vaccination in the tumor models of 3LL lung carcinoma and B16 melanoma, In both tumor models, immunization with 4 x 10(4) tumor RNA-pulsed Lptn-DCs induced more potent CTL activity, compared with their counterparts, specifically against tumor cells and Mut1 or tyrosinase-related protein 2 (TRP-2) peptide-pulsed RMA-S cells, and rendered the immunized mice resistant to tumor challenge much more effectively. CD8(+) T cells were necessary and sufficient to generate the protection of Lptn-DC-based RNA tumor vaccines, and CD4(+) T cells were required for the induction of tumor rejection. In the preestablished 3LL and B16 tumor models, vaccination with DC-based or LacZ-DC-based tumor RNA vaccines (2 x 10(5) cells) could reduce pulmonary metastasis and extend survival of tnmor-bearing mice, but was less effective than the Lptn-DC counterpart (with 60-80% mice surviving). When the immunizing dose was decreased to 4 x 10(4) cells, Lptn-DC-based tumor vaccines rather than their counterparts were still significantly effective. Our studies provide a potential strategy to improve the efficacy of DC-based vaccines, and a new approach to immunological intervention by chemokines.
Nonviral and Viral Gene Transfer Into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection

Andreas Lundqvist,Gabriele Noffz,Maxim Pavlenko,Stein Sæbøe-Larssen,Timothy Fong,Norman Maitland,Pavel Pisa

DOI: https://doi.org/10.1097/00002371-200211000-00001

IF: 4.912

2002-11-01

Journal of Immunotherapy

Abstract:Among the many promising cancer immunotherapeutic strategies, dendritic cells (DC) have become of particular interest. This study aims to optimize a clinical grade protocol for culture and transfection of human DC. Monocytes and CD34(+) hematopoietic stem cells (HSC) from same donor were differentiated under serum-free conditions and analyzed for their susceptibility to several recently described nonviral transfection methods as compared with established virally mediated gene transfer. Nonviral gene transfer methods studied were square-wave electroporation, lipofection, and particle-mediated transfer of plasmid DNA or in vitro transcribed mRNA. We conclude that DNA is not suitable for transduction of DC using nonviral methods. In contrast, mRNA and square-wave electroporation reproducibly yields 60% and 50% transfected monocyte- and CD34(+)-derived DC, respectively, measured at protein level, without affecting the cell viability. Thus, the transfection efficiency of this method is comparable with the 40-90% transgene expression obtained using retroviral (RV) or adenoviral (AdV) vectors in CD34(+)- and monocyte-derived DC, respectively. In monocyte-derived DC, however, the amount of protein expressed per-cell basis was higher after AdV (MOI = 1000) compared with mRNA electroporation-mediated transfer. This is the first study directly demonstrating side-by-side that mRNA electroporation into DC of different origin indeed results in a comparable number of transduced cells as when using virus-mediated gene transfer.

oncology,immunology,medicine, research & experimental
Correction: The Suppression of WRKY44 by GIGANTEA-miR172 Pathway Is Involved in Drought Response of Arabidopsis thaliana

Yingying Han,Xuan Zhang,Wei Wang,Yaofeng Wang,F. Ming

DOI: https://doi.org/10.1371/journal.pone.0124854

IF: 3.7

2015-04-06

PLoS ONE

Abstract:Dr. Wei Wang should be listed as third author for this study. Dr. Wang was responsible for analyzing sequences and creating Fig 5B. The authors apologize for this omission. The correct author list is: Yingying Han, Xuan Zhang, Wei Wang, Yaofeng Wang, Feng Ming Dr. Wei Wang’s affiliation is: Department of Biology, Howard Hughes Medical Institute-Gordon and Betty Moore Foundation, Duke University, Durham, North Carolina, United States of America. The summary of contributions to the study should be revised as below: Conceived and designed the experiments: FM YH. Performed the experiments: YH XZ. Analyzed the data: YH XZWWYW FM. Contributed reagents/materials/analysis tools: FM. Wrote the manuscript: YH. The correct citation is: Han Y, Zhang X, Wang W, Wang Y, Ming F (2013) The Suppression of WRKY44 by GIGANTEA-miR172 Pathway Is Involved in Drought Response of Arabidopsis thaliana. PLoS ONE 8(11): e73541. doi:10.1371/journal.pone.0073541
Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.

Hui Zhang,Yu Wang,Qian-Ting Wang,Sheng-Nan Sun,Shi-You Li,Hong Shang,You-Wen He

DOI: https://doi.org/10.3389/fcell.2020.00205

IF: 5.5

2020-01-01

Frontiers in Cell and Developmental Biology

Abstract:Dendritic cell (DC)-based vaccination is a promising immunotherapeutic strategy for cancer. However, clinical trials have shown only limited efficacy, suggesting the need to optimize protocols for human DC vaccine preparation. In this study, we systemically compared five different human DC vaccine maturation protocols used in clinical trials: (1) a four-cytokine cocktail (TNF-alpha, IL-6, IL-1 beta, and PGE2); (2) an alpha-DC-cytokine cocktail (TNF-alpha, IL-1 beta, IFN-alpha, IFN-gamma, and poly I:C); (3) lipopolysaccharide (LPS)/IFN-gamma; (4) TNF-alpha and PGE2; and (5) TriMix (mRNAs encoding CD40L, CD70, and constitutively active Toll-like receptor 4 electroporated into immature DCs). We found that the four-cytokine cocktail induced high levels of costimulatory and HLA molecules, as well as CCR7, in DCs. Mature DCs (mDCs) matured with the four-cytokine cocktail had higher viability than those obtained with the other protocols. Based on these features, we chose the four-cytokine cocktail protocol to further improve the immunizing capability of DCs by introducing exogenous genes. We showed that introducing exogenous Bcl-2 increased DC survival. Furthermore, introducing IL-12p70 rescued the inhibition of IL-12 secretion by PGE2 without impairing the DC phenotype. Introducing both Bcl-2 and IL-12p70 mRNAs into DCs induced enhanced cytomegalovirus pp65-specific CD8(+) T cells secreting IFN-gamma and TNF-alpha. Taken together, our data suggest that DC matured by the four-cytokine cocktail combined with exogenous Bcl-2 and IL-12p70 gene expression represents a promising approach for clinical applications in cancer immunotherapy.
mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy

Kosuke Sasaki,Yusuke Sato,Kento Okuda,Kazuki Iwakawa,Hideyoshi Harashima

DOI: https://doi.org/10.3390/pharmaceutics14081572

IF: 6.525

2022-07-28

Pharmaceutics

Abstract:Dendritic cells (DCs) are attractive antigen-presenting cells to be targeted for vaccinations. However, the systemic delivery of mRNA to DCs is hampered by technical challenges. We recently reported that it is possible to regulate the size of RNA-loaded lipid nanoparticles (LNPs) to over 200 nm with the addition of salt during their formation when a microfluidic device is used and that larger LNPs delivered RNA more efficiently and in greater numbers to splenic DCs compared to the smaller counterparts. In this study, we report on the in vivo optimization of mRNA-loaded LNPs for use in vaccines. The screening included a wide range of methods for controlling particle size in addition to the selection of an appropriate lipid type and its composition. The results showed a clear correlation between particle size, uptake and gene expression activity in splenic DCs and indicated that a size range from 200 to 500 nm is appropriate for use in targeting splenic DCs. It was also found that it was difficult to predict the transgene expression activity and the potency of mRNA vaccines in splenic DCs using the whole spleen. A-11-LNP, which was found to be the optimal formulation, induced better transgene expression activity and maturation in DCs and induced clear therapeutic antitumor effects in an E.G7-OVA tumor model compared to two clinically relevant LNP formulations.
Abstract B059: Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy

Khalid Rashid,Hailey R Lee,Amanda L Creech,Tony Luu,Katelyn Nguyen,Pu Lin Teng,Weihang Zhao,Alykhan M Premji,Evan R. Abt,Thuc M Le,Ting-Ting Wu,Norbert Pardi,Caius G Radu

DOI: https://doi.org/10.1158/2326-6074.tumimm24-b059

IF: 10.1

2024-10-19

Cancer Immunology Research

Abstract:The development of nucleoside-modified mRNA vaccines in ionizable lipid-containing nanoparticles (iLNPs) has established a robust cancer immunization platform targeting tumor-associated antigens (TAAs). The substitution of uridine (U) with N1-methylpseudouridine (m1ψ) in these vaccines abrogates innate immune activation, maximizes antigen expression, and enhances the in vivo priming and expansion of adoptively transferred naïve CD8+ T cells. However, antigen-specific T cells primed under immunosilent conditions with m1ψ mRNA-iLNPs exhibit suboptimal effector functions, including impaired cytotoxic cytokine secretion and memory development. Our laboratory has demonstrated that U-mRNA-iLNP vaccines, which elicit a strong type I IFN response, achieve more prolonged tumor growth suppression compared to m1Ψ-mRNA-iLNP vaccines in a preclinical murine model of melanoma. Despite this, the clinical translation of U-mRNA-iLNP vaccines is constrained by dose-limiting toxicities in humans, mediated by cytokines such as IL-1β and IL-6. To overcome this limitation, we explored the co-delivery of a tumor antigen-encoding m1Ψ mRNA-iLNP vaccine and type I IFN in m1ψ mRNA within the context of adoptive cell transfer. Our results demonstrate that prime-boost vaccination with an mRNA-iLNP vaccine, which allows for high antigen expression and a tunable type I IFN response, significantly increases the frequency of antigen-specific CD8+ T cells in circulation and secondary lymphoid organs. Transcriptional profiling of CD8+ T cell subsets expanded by our mRNA vaccine platform revealed a polyfunctional effector signature, including Ifng, Prf1, Gzmb, Tnfα, Klrg1, and Lamp1, as well as enhanced expression of interferon-stimulated genes and costimulatory receptors. We are currently assessing the in vivo efficacy of our mRNA-vaccine platform in melanoma and PDAC orthotopic and liver metastatic models. These studies aim to provide comprehensive mechanistic insights into the requirements of a cancer mRNA-vaccine to generate potent anti-tumor CD8+ T cell responses. Citation Format: Khalid Rashid, Hailey R Lee, Amanda L Creech, Tony Luu, Katelyn Nguyen, Pu Lin Teng, Weihang Zhao, Alykhan M Premji, Evan R. Abt, Thuc M Le, Ting-Ting Wu, Norbert Pardi, Caius G Radu. Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B059.

oncology,immunology
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

Cheryl L-L Chiang,Dawn A Maier,Lana E Kandalaft,Andrea L Brennan,Evripidis Lanitis,Qunrui Ye,Bruce L Levine,Brian J Czerniecki,Daniel J Powell Jr,George Coukos

DOI: https://doi.org/10.1186/1479-5876-9-198

2011-11-14

Abstract:Background: Dendritic cells (DCs) are the most potent antigen-presenting cell population for activating tumor-specific T cells. Due to the wide range of methods for generating DCs, there is no common protocol or defined set of criteria to validate the immunogenicity and function of DC vaccines. Methods: Monocyte-derived DCs were generated during 4 days of culture with recombinant granulocyte-macrophage colony stimulating factor and interleukin-4, and pulsed with tumor lysate produced by hypochlorous acid oxidation of tumor cells. Different culture parameters for clinical-scale DC preparation were investigated, including: 1) culture media; 2) culture surface; 3) duration of activating DCs with lipopolysaccharide (LPS) and interferon (IFN)-gamma; 4) method of DC harvest; and 5) cryomedia and final DC product formulation. Results: DCs cultured in CellGenix DC media containing 2% human AB serum expressed higher levels of maturation markers following lysate-loading and maturation compared to culturing with serum-free CellGenix DC media or AIM-V media, or 2% AB serum supplemented AIM-V media. Nunclon™Δ surface, but not Corning(®) tissue-culture treated surface and Corning(®) ultra-low attachment surface, were suitable for generating an optimal DC phenotype. Recombinant trypsin resulted in reduced major histocompatibility complex (MHC) Class I and II expression on mature lysate-loaded DCs, however presentation of MHC Class I peptides by DCs was not impaired and cell viability was higher compared to cell scraping. Preservation of DCs with an infusible cryomedia containing Plasma-Lyte A, dextrose, sodium chloride injection, human serum albumin, and DMSO yielded higher cell viability compared to using human AB serum containing 10% DMSO. Finally, activating DCs for 16 hours with LPS and IFN-γ stimulated robust mixed leukocyte reactions (MLRs), and high IL-12p70 production in vitro that continued for 24 hours after the cryopreserved DCs were thawed and replated in fresh media. Conclusions: This study examined criteria including DC phenotype, viability, IL-12p70 production and the ability to stimulate MLR as metrics of whole oxidized tumor lysate-pulsed DC immunogenicity and functionality. Development and optimization of this unique method is now being tested in a clinical trial of autologous oxidized tumor lysate-pulsed DC in clinical-scale in recurrent ovarian, primary peritoneal or fallopian tube cancer (NCT01132014).
Optimal Conditions for Adenoviral Transduction of Immature Dendritic Cells Without Affecting the Tolerogenic Activity of DC-Based Immunotherapy

Qian Jian,Zongli Fu,Hanyu Wang,Hanyuan Zhang,Yi Ma

DOI: https://doi.org/10.1016/j.jviromet.2024.114921

IF: 2.623

2024-03-30

Journal of Virological Methods

Abstract:Dendritic cells (DCs) play a pivotal role in maintaining immune tolerance. Using recombinant adenovirus (rAd) to deliver vectors to immature dendritic cells (imDCs) is an important method for studying the tolerogenic function of DCs. We found that using RPMI medium and a higher MOI during transduction increased the expression of CD80, CD86, and MHC-II on the surface of imDCs. Our data reveal a significant increase in the secretion of the pro-inflammatory cytokine IL-6 in the group showing the most pronounced phenotypic changes. In the mouse heart transplant model, imDCs with unstable phenotype and function due to adenoviral transduction resulted in an increased proportion of Th1 and Th17 cells in recipients. However, these effects can be managed, and our proposed optimized transduction strategy significantly minimizes these adverse effects. Our study holds significant implications for the development and optimization of immunotherapy utilizing tolerogenic dendritic cells.

biochemical research methods,biotechnology & applied microbiology,virology
Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier.

N. Ueno,E. Shpall,R. Champlin,Roy B. Jones

DOI: https://doi.org/10.1200/JCO.2004.06.922

IF: 45.3

2004-10-01

Journal of Clinical Oncology

Abstract:Progress in the treatment of high-risk and metastatic breast cancer has come slowly, particularly for patients with estrogen receptor– or progesterone receptor–negative, or hormone-unresponsive tumors. Trastuzumab is an encouraging example of the exploitation of a newer mechanism of action, monoclonal antibody–based immunotherapy, to produce antitumor effects in patients with metastatic tumor. Numerous trials of tumor-targeted therapeutics are underway, but none have yet demonstrated the potential to increase the cure rate for this disease, as has the newer generation of hormonal agents. New ideas and approaches are critical to improve the treatment of this disease. In hematologic diseases, major developments in transplant therapy are occurring as the result of the application of reduced-intensity allogeneic transplantation. These programs are based on two observations. First, engraftment of allogeneic progenitor cells and lymphocytes has produced major antitumor effects in patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, and lymphomas. This “allogeneic vaccine” can be given repeatedly until evidence of full donor T-cell chimerism, graft-versus-host disease (GVHD), or grafts-versus-tumor (GVT) effects occur. It remains unclear as to whether alloreactivity, lymphocyte reactivity against specific tumor antigens, or both, are the major therapeutic principles. Second, allogeneic engraftment can be produced using reduced-intensity immunosuppressive regimens. These regimens produce a low probability of visceral organ toxicity and GVHD when compared with fully myeloablative allogeneic transplantation. Thus, they are potentially applicable to broader patient populations, including older patients with major comorbid conditions. Full myeloablative allogeneic transplantation for breast cancer has been explored by several investigators; these studies have produced preliminary and indirect evidence for a graft– versus–breast cancer effect. More recently, reducedintensity allogeneic transplantation has been explored in patients with breast cancer and renal-cell carcinoma. In both settings, additional preliminary evidence for GVT has been reported. In addition, the use of cyclophosphamidebased immune modulation followed by infusion of tumorsensitized, ex vivo expanded autologous lymphocytes in melanoma patients has produced antitumor responses. Taken together, these observations demonstrate exciting leads for cellular immunotherapy of solid tumors. More generally, they raise the question of whether standard cytotoxic treatment could be followed quickly by lymphocyte infusions aimed at augmentation of tumor-specific immunoreactivity at a time at which the patient is usually immunosuppressed. In this issue of the Journal of Clinical Oncology, Bishop et al report the use of sibling-derived human leukocyte antigen–matched lymphocytes used as immunotherapy for patients with breast cancer. This carefully designed trial has several interesting features. An intensive regimen of cyclophosphamide and fludarabine was used to produce tumor control as well as to provide the immunosuppression required for engraftment of lymphocyte-depleted progenitor cells. T-cell– depleted peripheral blood progenitor cell allografts were also used, followed subsequently by planned donor lymphocyte infusions (DLIs) at intervals between 1 and 3 months post-transplantation. Finally, there was an independent assessment of antitumor effects during the first month (assigned causally to the chemotherapeutic regimen) and later responses (assigned causally to the DLI). It could be argued that the use of an immunosuppressive regimen lacking anti–breast cancer activity would have allowed the investigators to completely exclude chemotherapy as a JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 22 NUMBER 19 OCTOBER 1 2004
Dendritic Cell‐Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs

Yiming Cao,Jinrong Long,Huisheng Sun,Yiqi Miao,Ye Sang,Haitao Lu,Changxiao Yu,Zhen Zhang,Lin Wang,Jing Yang,Shengqi Wang

DOI: https://doi.org/10.1002/advs.202302423

IF: 15.1

2023-10-22

Advanced Science

Abstract:Abstract Spleen and lymphoid organs are important targets for messenger RNA (mRNA) delivery in various applications. Current nanoparticle delivery methods rely on drainage to lymph nodes from intramuscular or subcutaneous injections. In difficult‐to‐transfect antigen‐presenting cells (APCs), such as dendritic cells (DCs), effective mRNA transfection remains a significant challenge. In this study, a lymphatic targeting carrier using DC membranes is developed, that efficiently migrated to lymphoid organs, such as the spleen and lymph nodes. The nanoparticles contained an ionizable lipid (YK009), which ensured a high encapsulation efficacy of mRNA and assisted mRNA with endosomal escape after cellular uptake. Dendritic cell‐mimicking nanoparticles (DCMNPs) showed efficient protein expression in both the spleen and lymph nodes after intramuscular injections. Moreover, in immunized mice, DCMNP vaccination elicited Spike‐specific IgG antibodies, neutralizing antibodies, and Th1‐biased SARS‐CoV‐2‐specific cellular immunity. This work presents a powerful vaccine formula using DCMNPs, which represents a promising vaccine candidate for further research and development.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitro

Lantian Lu,Wei Yang Kong,Jiahui Zhang,Farrhana Firdaus,James W. Wells,Rachel J. Stephenson,Istvan Toth,Mariusz Skwarczynski,Jazmina L. Gonzalez Cruz

DOI: https://doi.org/10.3389/fimmu.2024.1298721

IF: 7.3

2024-02-27

Frontiers in Immunology

Abstract:Subunit vaccines hold substantial promise in controlling infectious diseases, due to their superior safety profile, specific immunogenicity, simplified manufacturing processes, and well-defined chemical compositions. One of the most important end-targets of vaccines is a subset of lymphocytes originating from the thymus, known as T cells, which possess the ability to mount an antigen-specific immune response. Furthermore, vaccines confer long-term immunity through the generation of memory T cell pools. Dendritic cells are essential for the activation of T cells and the induction of adaptive immunity, making them key for the in vitro evaluation of vaccine efficacy. Upon internalization by dendritic cells, vaccine-bearing antigens are processed, and suitable fragments are presented to T cells by major histocompatibility complex (MHC) molecules. In addition, DCs can secrete various cytokines to crosstalk with T cells to coordinate subsequent immune responses. Here, we generated an in vitro model using the immortalized murine dendritic cell line, DC2.4, to recapitulate the process of antigen uptake and DC maturation, measured as the elevation of CD40, MHC-II, CD80 and CD86 on the cell surface. The levels of key DC cytokines, tumor necrosis alpha (TNF-α) and interleukin-10 (IL-10) were measured to better define DC activation. This information served as a cost-effective and rapid proxy for assessing the antigen presentation efficacy of various vaccine formulations, demonstrating a strong correlation with previously published in vivo study outcomes. Hence, our assay enables the selection of the lead vaccine candidates based on DC activation capacity prior to in vivo animal studies.

immunology
Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid

Aikaterini Nasi,Tünde Fekete,Akilan Krishnamurthy,Stuart Snowden,Eva Rajnavölgyi,Anca I. Catrina,Craig E. Wheelock,Nancy Vivar,Bence Rethi

DOI: https://doi.org/10.4049/jimmunol.1300772

2013-08-16

The Journal of Immunology

Abstract:The demand for controlling T cell responses via dendritic cell (DC) vaccines initiated a quest for reliable and feasible DC modulatory strategies that would facilitate cytotoxicity against tumors or tolerance in autoimmunity. We studied endogenous mechanisms in developing monocyte-derived DCs (MoDCs) that can induce inflammatory or suppressor programs during differentiation, and we identified a powerful autocrine pathway that, in a cell concentration-dependent manner, strongly interferes with inflammatory DC differentiation. MoDCs developing at low cell culture density have superior ability to produce inflammatory cytokines, to induce Th1 polarization, and to migrate toward the lymphoid tissue chemokine CCL19. On the contrary, MoDCs originated from dense cultures produce IL-10 but no inflammatory cytokines upon activation. DCs from high-density cultures maintained more differentiation plasticity and can develop to osteoclasts. The cell concentration-dependent pathway was independent of peroxisome proliferator-activated receptor γ (PPARγ), a known endogenous regulator of MoDC differentiation. Instead, it acted through lactic acid, which accumulated in dense cultures and induced an early and long-lasting reprogramming of MoDC differentiation. Our results suggest that the lactic acid-mediated inhibitory pathway could be efficiently manipulated in developing MoDCs to influence the immunogenicity of DC vaccines.

immunology
Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

Michel Siegel,Aman Padamsey,Anna-Lena Bolender,Patrick Hargreaves,Johannes Fraidling,Axel Ducret,Katharina Hartman,Cary M Looney,Cristina Bertinetti-Lapatki,Olivier Rohr,Timothy P Hickling,Thomas E Kraft,Céline Marban-Doran

DOI: https://doi.org/10.3389/fimmu.2024.1406804

2024-08-20

Abstract:Introduction: Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies. Methods: To better understand the Dendritic Cell (DC) contribution to immunogenicity, we developed two flow cytometry-based assays: the DC internalization assay and the DC activation assay. Monocyte-derived dendritic cells (moDCs) were generated from peripheral blood mononuclear cells (PBMCs) and differentiated over a five-day period. The internalization assay measured the accumulation rate of therapeutic antibodies within moDCs, while the activation assay assessed the expression of DC activation markers such as CD40, CD80, CD86, CD83, and DC-SIGN (CD209). To characterize these two assays further, we used a set of marketed therapeutic antibodies. Results: The study highlights that moDCs differentiated for 5 days from freshly isolated monocytes were more prone to respond to external stimuli. The internalization assay has been shown to be highly sensitive to the molecule tested, allowing the use of only 4 donors to detect small but significant differences. We also demonstrated that therapeutic antibodies were efficiently taken up by moDCs, with a strong correlation with their peptide presentation on MHC-II. On the other hand, by monitoring DC activation through a limited set of activation markers including CD40, CD83, and DC-SIGN, the DC activation assay has the potential to compare a series of compounds. These two assays provide a more comprehensive understanding of DC function in the context of immunogenicity, highlighting the importance of both internalization and activation processes in ADA development. Discussion: The DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework.
Abstract 7249: Enhancing mRNA- lipid nanoparticles formulations to improve transfection efficiency in macrophages and dendritic cells in cancer immunotherapy

Yasir Alshehry,Matthew Fernandez,Raneem Aldaqqa,Asma Al-Terawi,Douglas Sweet,Sandro da Rocha

DOI: https://doi.org/10.1158/1538-7445.am2024-7249

IF: 11.2

2024-03-31

Cancer Research

Abstract:Cancer poses a global health challenge, driving the quest for innovative therapies. Messenger ribonucleic acid (mRNA) lipid nanoparticles (LNPs) are a promising strategy in cancer immunotherapy. However, a major obstacle lies in efficiently transfecting immune cells like macrophages and dendritic cells (DCs) with LNPs. This study seeks to improve cancer immunotherapy by optimizing mRNA-LNP formulations. Therefore, we systematically evaluated three components of LNPs, namely ionizable lipids, phospholipids, and sterols, and fine-tuned the components and their molar ratios. A comprehensive screening process was conducted to determine the efficiency of LNPs, involving in vitro experiments on macrophages and DCs, as well as in vivo assessments. Among six ionizable lipids assessed in different cell lines (RAW264.7 and DC2.4), SM-102 significantly enhanced the transfection efficiency in macrophages and DCs. Subsequently, we evaluated these LNPs in an in vivo setting. We quantified the bioluminescence signal after administering LNPs loaded with luciferase mRNA. The results demonstrated a significant increase in luciferase expression when using SM-102 and ALC-0315 lipids. To validate this finding, we conducted a T cell response study, which revealed an increased percentage of CD8+ T cells with SM-102-based LNPs compared to other formulations. Having identified SM-102 as a potent ionizable lipid, we proceeded to evaluate three phospholipids in vitro. The results indicated a significant enhancement in transfection efficiency with DOPE lipids compared to DSPC. Consequently, we selected DOPE as the phospholipid for subsequent screening. Lastly, we explored different types of sterols with varying molar ratios in macrophages and DC cells. Our findings unveiled a notable improvement in mRNA delivery, particularly in DCs, when the molar ratio of β-sitosterol was increased to 19.5%, while concurrently decreasing the molar ratio of cholesterol to 19% within the same formulation. It is noteworthy that the addition of β-sitosterol alone led to reduced transfection efficiency in DCs but resulted in a significant enhancement in macrophages. Lastly, we evaluated the top four formulations in vivo, and the results demonstrated a significant increase when β-sitosterol was added to the formulation with cholesterol, at molar ratios of 19.5% and 19%, respectively. Overall, altering lipid composition and their molar ratios profoundly impact mRNA-LNP transfection. The optimized formulations, comprising SM-102, DOPE, and cholesterol with or without β-sitosterol, outperformed the alternatives. These refined formulations hold promise for clinical applications, potentially enhancing passive therapeutic agent delivery into macrophages and DCs, offering promising prospects for advancing cancer immunotherapy. Citation Format: Yasir Alshehry, Matthew Fernandez, Raneem Aldaqqa, Asma Al-Terawi, Douglas Sweet, Sandro da Rocha. Enhancing mRNA- lipid nanoparticles formulations to improve transfection efficiency in macrophages and dendritic cells in cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7249.

oncology
A correlator sensor chip based on the integration of meta-materials and photonic crystals

Chunchen Lin,I. Mirza,Shouyuan Shi,D. Prather

DOI: https://doi.org/10.1109/MWSYM.2008.4633173

2008-06-15

Abstract:In this paper, we utilize advanced artificial materials, namely, photonic crystals (PhCs) and meta-materials, to construct a sensing head with miniaturized antennas as detecting devices and embedded signal channelization for preprocessing. We experimentally demonstrated miniaturized antennas based on meta-materials, as well as, hybrid lattice PhCs and Schottky diodes for RF channelization. To further decrease the size of the system, we also present our initial design and simulation results for a PhC slow wave delay line, which also functions as a waveguide to the channelized signals.
Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice

Wenzhi Li,Xiang Wang,Renfu Chen,Haitao Zhu,Gang Chen,Xiaoqing Sun

DOI: https://doi.org/10.1016/j.jss.2011.12.009

IF: 2.417

2012-01-01

Journal of Surgical Research

Abstract:Background. Co-stimulatory molecules are pivotal for T cell activation. It is increasingly recognized that programmed death ligand 1 (PD-L1) is a novel costimulatory molecule, which raises the question as to whether PD-L1 regulates T cell responses. This study aimed to investigate the inhibitory effects of PD-L1 on T cell activation. Materials and Methods. We constructed a transgenic vector containing the complete PD-L1 gene, which interacts with the inhibitory receptor PD-1 in T cell-mediated immune activation. Donor dendritic cells (DCs) derived from C57BL/6 mice were transfected with PD-L1 and mixed with allogeneic, recipient T cells from BALB/c mice. The T cell activation was determined by the MTT assay and T cell proliferation was determined using carboxyfluoroscein succinimidyl ester (CFSE)-labeling following in vitro mixed leukocyte reactions. Results. The expression of PD-L1 protein in PD-L1-transfected DCs was 47.97% +/- 1.06%, compared with 4.66% +/- 0.76% and 5.30% +/- 0.60% in blank and negative controls, respectively (P < 0.05). PD-L1 protein was effectively expressed in DCs. Furthermore, in DCs stably transfected with PD-L1, T cell activation was significantly suppressed and T cell proliferation rate was decreased by 35% compared with untransfected DCs (P < 0.05). Conclusion. PD-L1 delivers an immunoinhibitory signal, suppressing T cell activation. Overexpression of PD-L1 signaling induces tolerance, which presents a promising immunotherapeutic approach for long-term graft acceptance. (C) 2012 Elsevier Inc. All rights reserved.
Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

XT Cao,WP Zhang,L He,ZL Yuan,ZF Xie,SH Ma,H Hamada,JL Wang

DOI: https://doi.org/10.4049/jimmunol.161.11.6238

1998-01-01

The Journal of Immunology

Abstract:Dendritic cells (DC) are regarded as attractive candidates for cancer immunotherapy. Our aim is to improve the therapeutic efficacy of DC-based tumor vaccine by augmenting DC preferential chemotaxis on T cells. Mouse bone marrow-derived DC were transduced with lymphotactin (Lptn) gene by adenovirus vector. The supernatants from Lptn gene-modified DC (Lptn-DC) were capable of attracting CD4+ and CD8+ T cells in a chemotaxis assay, whereas their mock control could not. Lptn expression of Lptn-DC was further confirmed by RT-PCR. Lptn-DC were pulsed with Mut1 peptide and used for vaccination. Immunization with the low dose (1 x 10(4)) of Mut1 peptide-pulsed DC induced weak CTL activity, whereas the same amounts of Mut1 peptide-pulsed Lptn-DC markedly induced specific CTL against 3LL tumor cells. A single immunization with 1 x 10(4) Mut1 peptide-pulsed Lptn-DC could render mice resistant to a 5 x 10(5) 3LL tumor cell challenge completely, but their counterpart could not. The protective immunity induced by Mut1 peptide-pulsed Lptn-DC depends on both CD4+ T cells and CD8+ T cells rather than NK cells in the induction phase and depends on CD8+ T cells rather than CD4+ T cells and NK cells in the effector phase. Moreover, the involvement of CD28/CTLA4 costimulation pathway and IFN-gamma are also necessary. When 3LL tumor-bearing mice were treated with 1 x 10(4) Mut1 peptide-pulsed Lptn-DC, their pulmonary metastases were significantly reduced, whereas the same low dose of Mut1 peptide-pulsed DC had no obvious therapeutic effects. Our data suggest that Lptn-DC are more potent adjuvants for peptide delivery to induce protective and therapeutic antitumor immunity.
MODULATION OF TUMORICIDAL ACTIVITIES OF DENDRITIC CELLS TO ENHANCE ANTIGEN UPTAKE AND CROSS-PRESENTATION

Kathryn Knoop,Nachiket Kumar,B. Butler,S. K. Sakthivel,R. Taylor,Tomonori Nochi,H. Akiba,H. Yagita,Hiroshi Kiyono,Ifor Williams

2005-01-01

Abstract:Abstract Dendritic cells (DCs) are professional antigen-presenting cells that are integral to the induction of primary, antigen-specific T cell responses. In the cancer setting, DCs mediate cross-priming of tumor-reactive T cells by presenting tumor antigens acquired from viable or dead cancer cells. Due to their unique functional properties, DCs have been utilized as both vectors and targets for immunological intervention in numerous diseases and are optimal candidates for vaccination protocols in cancer. In addition to their antigen presentation function(s), recent evidence suggests that DCs may also perform an innate immune effector function, with human DCs reported to mediate direct tumoricidal activity in vitro. However, the mechanism(s) by which DCs directly kill tumor cells remain unclear. The goal of this study is to further characterize the mechanism(s) associated with murine DC tumoricidal function and to determine whether and how this function may be enhanced to promote anti-tumor immune responses that translate into therapeutic effectiveness. One way we sought to enhance this DC effector function was through the genetic engineering of DCs themselves. After transduction with mIL-12 and/or mIL-18 cDNA using recombinant adenoviral vectors, DCs exhibited significantly elevated tumor killing activity. This was mediated, at least in part, by TNF ligand-receptor complexes, as demonstrated by antibody blocking assays. When injected in situ, these engineered DCs exhibited prolonged survival, in association with enhanced levels of tumor apoptosis proximal to imaged DCs and our capacity to image DC that had engulfed tumor apoptotic bodies. We also observed notable therapeutic benefits upon intratumoral delivery of these DCs in concert with an expanded in vivo repertoire of anti-tumor CD8+ T cells. In addition to DC modification, we also evaluated treatments applied to tumor cells that resulted in enhanced sensitivity to (control) DC-mediated killing. Specifically, we found that pretreatment of A20 lymphoma cells with a nitric oxide (NO) donor compound, PAPA-NO, markedly increased the sensitivity of tumor cells to consequent apoptosis mediated by DCs. This appeared to provide DCs with a preferred source of tumor antigens, with which, they were capable of activating specific T cells via a cross-presentation pathway. We have also discovered that multiple TNF family ligands participated in DC-mediated tumoricidal function and that tumor cell-expressed survivin may represent a critical downstream factor regulating the apoptotic sensitivity of tumor cells to DC-mediated apoptosis. When taken together, these studies provide novel details regarding mechanisms involved in DC anti-tumor effector function, and suggest two DC-based, combinational cancer therapies that target the effective cross-priming of therapeutic T cells. The results presented in this dissertation support an efficient model in which DCs may not only serve as the gatherers and presenters of antigens, but also the hunters as well, with tumoricidal activity mediated via TNF family ligands.
Abstract 6744: Activating anti-MDS immunity with polarized dendritic cell vaccines

Daniel Alvarado,Jennifer Peresie,Adam Brinkman,Cheryl Allen,Weijian Jiang,Pawel Kalinski,Tiffany Tanaka,Elizabeth Griffiths,Michael Nemeth

DOI: https://doi.org/10.1158/1538-7445.am2024-6744

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Less than 50% of patients with higher-risk myelodysplastic syndromes (MDS) show clinical response to standard-of-care hypomethylating (HMA) therapy. Significant enthusiasm existed for immunotherapy/HMA combinations for these patients, but studies have failed to deliver on the initial promise. We have demonstrated that patients with MDS have a deficiency in antigen-presenting cells, called CD141Hi dendritic cells (DC). DC-deficient MDS patients have reduced response to HMAs, worse overall survival, and show less response to cancer vaccination. We hypothesized that restoration of this population using a novel DC vaccination approach - alpha-type-1 polarized dendritic cells (αDC1) - might compensate for this deficiency and restore immunity. To generate αDC1s, we collected monocytes from MDS patients and healthy donors (HD) and cultured them for 6 days in vitro in the presence of recombinant human GM-CSF and IL-4 followed by an additional 18-24 hours in the presence of αDC1 maturation factors (poly-I:C/IFNα/IFNγ/TNFα/IL-1β). Overall, we attempted to generate αDC1s from 15 MDS samples; 13/15 exhibited intermediate to very high-risk disease and 10/15 are currently receiving HMA therapy. We successfully cultured cells from 8/15 samples (53%). Of the 8 MDS samples, 5 were collected from patients receiving HMA therapy (62.5%). We were unable to successfully culture αDC1s from the other 5 patients receiving HMA therapy, and thus the effect of HMA therapy on aDC1 generation remains unclear. To test the function of MDS αDC1s, we focused on two signals necessary to activate immune responses: 1) the expression of co-stimulatory molecules and 2) the production of IL-12p70. Flow cytometric analysis on αDC1s and immature DCs from MDS samples revealed intra-patient variation in the fold-change surface expression of CD40/80/83/86 and HLA-DR proteins. Additionally, there was a trend towards decreased up-regulation of CD80 and CD86 in MDS specimens compared to HD. To assess production of IL-12p70, we stimulated immature DCs and αDC1s with CD40L and performed ELISA analysis on the media supernatant. We found that 3 out of 4 samples could produce IL-12p70 (range 27 - 5,480 pg/ml). To date, our results suggest that generation of MDS patient-derived αDC1 cells is feasible and additional work is being performed to fully characterize their ability to activate anti-MDS immune responses. Since αDC1s have an established safety profile in patients with solid tumors, we anticipate that we will be able to rapidly translate our results to the clinic. Citation Format: Daniel Alvarado, Jennifer Peresie, Adam Brinkman, Cheryl Allen, Weijian Jiang, Pawel Kalinski, Tiffany Tanaka, Elizabeth Griffiths, Michael Nemeth. Activating anti-MDS immunity with polarized dendritic cell vaccines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6744.

oncology

P2Y12 antibody inhibits platelet activity and protects against thrombogenesis.

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Nonviral and Viral Gene Transfer Into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection

Correction: The Suppression of WRKY44 by GIGANTEA-miR172 Pathway Is Involved in Drought Response of Arabidopsis thaliana

Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.

mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy

Abstract B059: Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

Optimal Conditions for Adenoviral Transduction of Immature Dendritic Cells Without Affecting the Tolerogenic Activity of DC-Based Immunotherapy

Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier.

Dendritic Cell‐Mimicking Nanoparticles Promote mRNA Delivery to Lymphoid Organs

Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitro

Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

Abstract 7249: Enhancing mRNA- lipid nanoparticles formulations to improve transfection efficiency in macrophages and dendritic cells in cancer immunotherapy

A correlator sensor chip based on the integration of meta-materials and photonic crystals

Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice

Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

MODULATION OF TUMORICIDAL ACTIVITIES OF DENDRITIC CELLS TO ENHANCE ANTIGEN UPTAKE AND CROSS-PRESENTATION

Abstract 6744: Activating anti-MDS immunity with polarized dendritic cell vaccines